management team  selecta biosciences incselecta biosciences inc   about about selecta management team board of directors selecta russia collaborations contact platform svp™ platform svp™ for immune tolerance svp™ for immune stimulation publications pipeline pipeline overview mitigation of antidrug antibodies mitigation of antidrug antibodies gout gene therapy oncology allergies  autoimmune diseases therapeutic vaccines prophylactic vaccines investors  media investor overview press releases events  presentations stock information stock quote  chart historical price lookup investment calculator corporate governance highlights management team board of directors committee composition financial information sec filings annual reports annual meeting investor resources investor faqs ir contacts email alerts careers careers at selecta contact     management team werner cautreels phd president and ceo prior to joining selecta biosciences inc in  dr cautreels was chief executive officer of solvay pharmaceuticals the pharmaceuticals division of the solvay group in brussels belgium from  until solvay pharmaceuticals was acquired by abbott laboratories in  before becoming the ceo of solvay pharmaceuticals dr cautreels was its global head of rd prior to joining solvay he was with nycomed‑amersham and spent  years at sanofi sterling‑winthrop serving in a variety of rd management positions in europe and the united states dr cautreels is a director of galapagos nv in mechelen belgium he also previously held director positions at seres therapeutics inc innogenetics nv and arqule inc additionally dr cautreels was previously the president of the belgian‑luxemburg chamber of commerce for russia and belarus he received his phd in chemistry specializing in mass spectrometry from the university of antwerp antwerp belgium and his financial and business training from the advanced management program at harvard business school read more lloyd johnston phd chief operating officer and senior vice president research and development prior to joining selecta biosciences inc in  dr johnston spent nine years at alkermes inc ascending to the role of vice president of operations with responsibility for process development scale‑up and clinical manufacturing of pulmonary and sustainedrelease injectable products as well as leadership of alkermes’ manufacturing facility in chelsea massachusetts he was also a project leader and a member of steering committees at alkermes for numerous products through various stages of development from phase  through registration dr johnston was an original member of advanced inhalation research inc or air a private company formed in  and acquired by alkermes in  prior to joining air he was a lecturer in the department of chemical engineering at the university of new south wales in sydney australia he received his bsc in chemical engineering from queen’s university in ontario canada and his ms and phd in chemical engineering from the massachusetts institute of technology mit read more takashi kei kishimoto phd chief scientific officer prior to joining selecta biosciences inc in  dr kishimoto was vice president of discovery research at momenta pharmaceuticals inc where he served in several leadership positions over the course of five years and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation oncology and cardiovascular disease prior to momenta he served as senior director of inflammation research at millennium pharmaceuticals inc from  to  where he provided the scientific leadership for four programs in clinical development and as an associate director of research at boehringer ingelheim pharmaceuticals dr kishimoto has published over  peer‑reviewed articles in scientific journals including nature science cell and the new england journal of medicine dr kishimoto received his ba from new college of the university of south florida and his phd in immunology from harvard university read more peter keller msci chief business officer mr keller joined selecta biosciences inc from abbott laboratories in  in addition to his role as chief business officer mr keller leads selecta’s gene therapy programs after the acquisition of solvay pharmaceuticals in  by abbott laboratories he led the integration process for five rd and manufacturing facilities in europe before the acquisition mr keller was vice president head of mergers  acquisitions and alliance management at solvay pharmaceuticals where he negotiated license and acquisition agreements in various therapeutic areas such as vaccines neurology and cardiology he was the lead negotiator for the  billion fenofibrate alliance between solvay pharmaceuticals and abbott laboratories and was instrumental in the  billion acquisition of solvay pharmaceuticals by abbott laboratories mr keller previously spent nearly a decade as a management consultant at mckinsey  company and simon kucher  partners he received his msci in industrial engineering and management from the technical university of karlsruhe in karlsruhe germany read more david abraham jd general counsel chief compliance officer and corporate secretary prior to joining selecta biosciences inc in  mr abraham was a member of innovation legal group a boutique intellectual property law firm and was executive director for patents at durect corporation a specialty pharmaceutical company he previously served as senior patent counsel for alza corporation alza a johnson  johnson company prior to these roles mr abraham was employed by the law firms of wilson sonsini goodrich and rosati and finnegan henderson farabow garrett and dunner he also was a patent examiner at the united states patent and trademark office mr abraham received his bs in chemical engineering from the university of rochester and his jd from the george washington university law school read more earl sands md chief medical officer dr sands joined selecta biosciences inc in   he previously served as chief medical officer of targacept inc now part of catalyst biosciences a biopharmaceutical company where he was responsible for designing and implementing targacept’s clinical trials as well as providing strategic and scientific input on intellectual property matters and in‑licensing opportunities prior to targacept dr sands was the chief medical officer of plasma surgical inc a developer of surgical and therapeutic applications where he was responsible for strategic integrated clinical development plans and execution dr sands also previously served as president of alpha med solutions llc a consulting firm he served in various capacities over the course of eight years at solvay pharmaceuticals which included executive vice president market access senior vice president of rd acting chief medical officer and director of women’s health previously dr sands served as senior regional medical director professional and scientific relations at procter  gamble pharmaceuticals was a founding partner and medical director at innovation in medical education and training was a managing partner of women’s health care pc and was chairman of the obgyn department at pottstown memorial medical center in pottstown pennsylvania dr sands received his ba in premedical sciences from lehigh university and his md from hahnemann university school of medicine read more david siewers chief financial officer and treasurer mr siewers has  years of experience in financial management financial systems design and implementation equity and debt financing and mergers and acquisitions prior to joining selecta biosciences inc mr siewers was an independent financial consultant providing strategic guidance and tactical implementation of accounting systems management and regulatory reporting internal controls profitability and cost analysis to an array of clients ranging from startups to mid‑level companies previously mr siewers held various positions in the financial services industry including senior vice president and divisional chief financial officer roles within fleet financial group and senior vice president of putnam investments he received his bs in accounting from marietta college and earned his cpa in 7 while working at kpmg read more dmitry ovchinnikov phd managing director selectarus llc dr ovchinnikov joined selecta’s russian operation in  prior to this he was a medical director for zao sandoz russia a novartis company and was responsible for medical support and compliance clinical trials and pharmacovigilance dr ovchinnikov was also a member of the russia executive committee at sandoz and took part in the elaboration of the development strategy for the russian branch prior to sandoz dr ovchinnikov spent four years at janssencilag a johnson  johnson company as a medical manager for russia and the commonwealth of independent states and also served as a clinical research associate for parexel rus llc a life sciences consulting firm and a division of parexel international dr ovchinnikov received his ms and phd in biochemistryoncologyvirology from lomonosov moscow state university in moscow russia read more   selecta biosciences inc all rights reserved    contact    sitemap   privacy policy    jobs at selecta biosciences       follow selectabio selecta biosciences appoints takashi kei kishimoto phd as chief scientific officer  business wire selecta biosciences appoints takashi kei kishimoto phd as chief scientific officer august    am eastern daylight time watertown massbusiness wireselecta biosciences inc a biopharmaceutical company developing novel targeted vaccines and immunotherapies announced today that takashi kei kishimoto phd has been appointed as chief scientific officer dr kishimoto brings more than  years of experience as a pharmaceutical and biotechnology scientist and leader he will report directly to werner cautreels phd chief executive officer of selecta biosciences we are extremely pleased that kei will be joining our team to lead selectas scientific activities said werner cautreels phd chief executive officer of selecta biosciences kei’s experience will help to accelerate the advancement of our broad platform of synthetic vaccine particle svp™ product candidates which we view as central to leveraging the vast potential of selectas novel technology platforms selectas breakthrough technology based on selfassembling synthetic nanoparticles creates a new paradigm in vaccine development enabling completely new therapeutic applications with improved efficacy and safety profiles i am excited to have this opportunity to help develop the nextgeneration of therapeutic and prophylactic vaccines selectas unique synthetic vaccine particle svp™ platform has the potential to radically change how serious diseases such as cancer autoimmune diseases allergies and chronic infectious diseases are treated said dr kishimoto selecta’s broad technology platform has the power to both stimulate potent and protective immune responses as well as dampen deleterious immune responses in an antigenspecific manner prior to joining selecta dr kishimoto was vice president of research at momenta pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products for inflammation oncology and cardiovascular disease previously he was senior director of inflammation research at millennium pharmaceuticals where he provided the scientific leadership for four programs in clinical development and was an associate director of research at boehringer ingelheim dr kishimoto has published over  peerreviewed articles in scientific journals including nature science cell and the new england journal of medicine dr kishimoto received his doctoral degree in immunology from harvard university and his postdoctoral training at stanford university about selecta selecta biosciences inc is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigenspecific immune activation or antigenspecific immune tolerance for therapeutic and prophylactic applications selectas proprietary synthetic vaccine particle svp™ platform creates a new paradigm in vaccine development enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles selecta’s fully synthetic engineering of novel vaccines offers a number of compelling benefits including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes selecta’s svp™ platform technology is flexible to enable diverse vaccines and the company has created targeted antigenspecific synthetic vaccine particles tsvp™ and targeted antigenspecific tolerogenic synthetic vaccine particles tsvp™ targeted synthetic vaccine particles tsvp™ activate immune responses to a wide array of relevant antigens including small molecules peptides oligosaccharides and proteins these particles can target humoral or cellular pathways of the immune system examples for applications include cancer infectious diseases and addiction targeted tolerogenic synthetic vaccine particles tsvp™ are designed to induce antigenspecific immune tolerance examples for applications include autoimmune diseases allergies and transplant rejection selecta’s pipeline currently contains a vaccine for smoking cessation and relapse prevention a vaccine for type  diabetes vaccines for several infectious diseases universal influenza universal human papillomavirus and malaria and research approaches with cancer vaccines and in the field of allergies building on the company’s novel approach selecta’s product candidates have the potential to become firstinclass or bestinclass therapeutics to treat and prevent diseases selecta biosciences is based in watertown massachusetts usa for more information please visit wwwselectabiocom contacts the yates networkkathryn morris kathryntheyatesnetworkcom release summary selecta biosciences announced that takashi kei kishimoto phd has been appointed as chief scientific officer contacts the yates networkkathryn morris kathryntheyatesnetworkcom search advanced news search advanced news search log in sign up takashi kei kishimoto  selecta biociences usa  vaccines rdinternational conference on vaccines  vaccination july   embassy suites las vegas usa recommended global vaccines conferences usa  americas vaccines congress  usa vaccines delivery  usa vaccines  usa europe  middle east vaccines summit  uk vaccines congress  uae euro vaccines  spain vaccine design  austria asia pacific vaccines asia pacific  japan immunization meeting  japan vaccines world australia search  events omics international organises  global conferenceseries events every year across usa europe  asia with support from  more scientific societies and publishes 7 open access journals which contains over  eminent personalities reputed scientists as editorial board members for more conferences visit wwwconferenceseriescom back related conferences vaccines congress  usa vaccines delivery  usa vaccines  usa vaccines summit  uk vaccines congress  uae euro vaccines  spain vaccine design  austria vaccines asia pacific  japan immunization meeting  japan vaccines world australia know more subject wise global events medical agri food  aqua physics chemistry clinical environmental eee chemical engineering pharma genetics health care immunology massmedia materials science environmental business  management veterinary molecular biology neuroscience nursing physics microbiology  conferences  conferences regionwise conferences conference destination map previous conferences takashi kei kishimoto selecta biociences usa title rational design of synthetic vaccine particles svp for therapeutic treatment of chronic diseases biography dr kishimoto is the chief scientific officer of selecta biosciences a biotechnology company developing synthetic vaccines based on a novel selfassembling nanoparticle technology prior to joining selecta he was vice president of research at momenta pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products previously he held leadership positions at millennium pharmaceuticals and boehringer ingelheim dr kishimoto has published over  peerreviewed articles including articles in nature science cell and the new england journal of medicine dr kishimoto received his doctoral degree in immunology from harvard university and his postdoctoral training at stanford university abstract vaccines for the prophylaxis of infectious diseases have been one of the most effective interventions for improving human health recent advances in immunology and vaccine technology have opened the door to novel vaccinebased therapies for the therapeutic treatment of chronic diseases we have developed a flexible and modular synthetic vaccine particle svp technology that enables the rational design of both stimulatory vaccines and tolerogenic immune therapies our targeted svps tsvp have been designed and optimized to promote efficient crosspresentation of antigen and stimulate robust cellular immunity for the treatment of cancer and chronic infections while our tolerogenic targeted svps tsvp are designed to induce immune tolerance for the treatment of autoimmune diseases allergies and immunogenicity of biological therapies we will describe the general design principles of these synthetic selfassembling nanoparticles and provide examples for use in various disease settings videos photos  featured speaker presentation videos sevil sonmez university of central florida addiction therapy  orlando florida usa  august   chunbae kim yonsei university republic of korea addiction therapy  orlando florida usa  august   elizabeth halpern federal university of rio de janeiro brazil addiction therapy  orlando florida usa  august   monika heidemarie seltenhammer medical university of vienna austria addiction therapy  orlando florida usa  august   jennifer loftis oregon health  science university usa addiction therapy  orlando florida usa  august   christina santini kildehoej private hospital denmark addiction therapy  orlando florida usa  august   sushil sharma saint james school of medicine the netherlands addiction therapy  orlando florida usa  august   ehab sayed ramadan tanta university egypt addiction therapy  orlando florida usa  august   alaaeldin a elkoussi assiut university egypt addiction therapy  orlando florida usa  august   deanna mulvihill registered nurse multistate privilegeusa addiction therapy  orlando florida usa  august   adi jaffe alternatives behavioral health llc usa addiction therapy  orlando florida usa  august   rocco de filippis institute of psychopathology italy addiction therapy  orlando florida usa  august   cynthia stuhlmiler university of new england australia addiction therapy  orlando florida usa  august   sarah c herremans universitair ziekenhuis brussel belgium addiction therapy  orlando florida usa  august   talakad n sathyaprabha national institute of mental health and neurosciences india addiction therapy  orlando florida usa  august   prapapun chucharoen mahidol university thailand addiction therapy  orlando florida usa  august   bangon thepthien mahidol university thailand addiction therapy  orlando florida usa  august   lacha rueangkit mahidol university thailand addiction therapy  orlando florida usa  august   arash ghodousi islamic azad university iran addiction therapy  orlando florida usa  august   e renea snyder pennsylvania department of corrections usa addiction therapy  orlando florida usa  august   conferences albums drug discovery congress  bangkok thailand july   bariatric surgery  rome italy child psychiatry  chicago illinios usa july   natural hazards congress  osaka japan june   clinmicrobiology  avani atrium bangkok bangkok thailand july   advanced dentistry  las vegas usa may   pediatric cardiologists  london uk april   virology asia  singapore may   global cancer  osaka japan may 7  proteomics  osaka japan may   pharmaceutical sciences  amsterdam netherlands february 7   diabetes global  rome italy march   world oncologists san francisco usa november   aqua europe  madrid spain march   agri world  amsterdam netherlands march   materials research  berlin germany golden tulip berlin hotel hamburg february   euro mass spectrometry  london uk june   holiday inn london  brentford lock medicinal chemistry  milan italy june   microbiology summit  amsterdam netherlands february 7  euro organic chemistry  amsterdam netherlands march   more related journals journal of vaccines  vaccination journal of clinical  cellular immunology immunome research journal of immunological techniques in infectious diseases know more open access journals agri and aquaculture biochemistry bioinformatics  systems biology biomedical sciences business  management chemical engineering chemistry clinical sciences computer science economics  accounting engineering environmental sciences food  nutrition general science genetics  molecular biology geology  earth science immunology  microbiology informatics materials science mathematics medical sciences nanotechnology neuroscience  psychology nursing  health care pharmaceutical sciences physics plant sciences social  political sciences veterinary sciences speaker presentations pdfs speaker pdfs ‹ › × × previous next selecta chooses takashi kei kishimoto for cso  scrip in order to deliver a personalized responsive service and to improve the site we remember and store information about how you use it this is done using simple text files called cookies which sit on your computer by continuing to use this site and access its features you are consenting to our use of cookies to find out more about the way informa uses cookies please go to our cookie policy page scrip is part of the business intelligence division of informa plc informa plc about us investor relations talent this site is operated by a business or businesses owned by informa plc and all copyright resides with them informa plc’s registered office is  howick place london swp wg registered in england and wales number  informa toggle menu menu other publications in vivo  medtech insight  pink sheet  rose sheet  register sign in this copy is for your personal noncommercial use for highquality copies or electronic reprints for distribution to colleagues or customers please call      printed by usernamepublicrestriction already registered sign in to continue reading your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at   7   us support at  7 7  or onlineaccessinformacom new to scrip request a free trial today free trial register for our free email digests your username does not meet the requirements an account with that username already exists unfortunately weve not been able to process your registration please contact support register toggle menu menu home commercial companies deals strategy market access market intelligence appointments research  development clinical trials approvals therapy areas pipeline watch policy  regulation hot topics us election  pricing debate brexit regional coverage meet the team scrip awards scrip  scrip asia  ask the analyst pdf library rss feeds free trial request subscribe advertise usernamepublicrestriction already registered sign in to continue reading your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at   7   us support at  7 7  or onlineaccessinformacom new to scrip request a free trial today free trial register for our free email digests your username does not meet the requirements an account with that username already exists unfortunately weve not been able to process your registration please contact support register ask the analyst email print bookmark share tags orthopedics inflammation selecta chooses takashi kei kishimoto for cso this article was originally published in scrip  sep  news gemma sharman gemmasharmaninformacom executive summary selecta biosciences a biopharmaceutical company developing novel targeted vaccines and immunotherapies has appointed dr takashi kei kishimoto chief scientific officer reporting to dr werner cautreels selectas ceo dr kishimoto most recently served as vicepresident of research at momenta pharmaceuticals where he led a team advancing novel and complex generic products for inflammation oncology and cardiovascular disease already registered sign in to continue reading your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at   7   us support at  7 7  or onlineaccessinformacom new to scrip request a free trial today free trial register for our free email digests your username does not meet the requirements an account with that username already exists unfortunately weve not been able to process your registration please contact support register table view full table advertisement topics therapy areas orthopedics inflammation related companies momenta pharmaceuticals inc related deals momenta pharmaceuticals inc advertisement ask the analyst email print bookmark share tags orthopedics inflammation you must sign in to use this functionality your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at   7   us support at  7 7  or onlineaccessinformacom authenticationsigninheadsigninheader your login andor password information does not match our records please try again forgot your password remember me sign in thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at   7   us support at  7 7  or onlineaccessinformacom usernamepublicrestriction register your username does not meet the requirements sorry  this email domain is not allowed sorry  public email accounts are not allowed please provide a work email address an account with that username already exists unfortunately weve not been able to process your registration please contact support register sc ask the analyst please note you can also click below link for ask the analyst ask the analyst all set this question has been sent to myemailaddress all fields are required please make sure all fields are completed please make sure you have filled out all fields please make sure you have filled out all fields please enter a valid email address please enter a valid phone number ask your question to our analysts cancel send sc email article all set this article has been sent to myemailaddress all fields are required for multiple recipients separate email addresses with a semicolon please make sure all fields are completed please enter a valid email address please make sure you have filled out all fields please make sure you have filled out all fields subject selecta chooses takashi kei kishimoto for cso add a personalized message to your email cancel send please note only individuals with an active subscription will be able to access the full article all other readers will be directed to the abstract and would need to subscribe sign in to set a search alert your login andor password information does not match our records please try again forgot your password remember me your alert for will be saved to your account  saved searches and alerts log in  save thanks weve sent a link to reset your password forgot your password   enter the email address associated with your account and an email will be sent to you to reset your password please enter a valid email address unfortunately weve not been able to process this request submit need help please call uk support at   7   us support at  7 7  or onlineaccessinformacom × this copy is for your personal noncommercial use for highquality copies or electronic reprints for distribution to colleagues or customers please call      printed by takashi kei kishimoto  selecta biociences usa   omics international international conferences submit meet inspiring speakers and experts at our  global conferenceseries events with over  conferences  symposiums and  workshops on medical pharma engineering science technology and business explore and learn more about conference series ltd world’s leading event organizer   related conferences subject wise global events medical agri food  aqua chemical engineering physics chemistry clinical earth  environmental sciences eee chemical engineering pharma genetics health care immunology massmedia materials science environmental business  management veterinary molecular biology neuroscience nursing microbiology  conferences  conferences regionwise conferences conference destination map previous conferences takashi kei kishimoto selecta biociences usa title rational design of synthetic vaccine particles svp for therapeutic treatment of chronic diseases biography dr kishimoto is the chief scientific officer of selecta biosciences a biotechnology company developing synthetic vaccines based on a novel selfassembling nanoparticle technology prior to joining selecta he was vice president of research at momenta pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products previously he held leadership positions at millennium pharmaceuticals and boehringer ingelheim dr kishimoto has published over  peerreviewed articles including articles in nature science cell and the new england journal of medicine dr kishimoto received his doctoral degree in immunology from harvard university and his postdoctoral training at stanford university abstract vaccines for the prophylaxis of infectious diseases have been one of the most effective interventions for improving human health recent advances in immunology and vaccine technology have opened the door to novel vaccinebased therapies for the therapeutic treatment of chronic diseases we have developed a flexible and modular synthetic vaccine particle svp technology that enables the rational design of both stimulatory vaccines and tolerogenic immune therapies our targeted svps tsvp have been designed and optimized to promote efficient crosspresentation of antigen and stimulate robust cellular immunity for the treatment of cancer and chronic infections while our tolerogenic targeted svps tsvp are designed to induce immune tolerance for the treatment of autoimmune diseases allergies and immunogenicity of biological therapies we will describe the general design principles of these synthetic selfassembling nanoparticles and provide examples for use in various disease settings related journals subject wise open access journals agri food aqua  vet business  management chemical engineering chemistry clinical dental  oral health earth  environmental sciences eee engineering genetics  molecular biology immunology  microbiology material science mathematics medical neurology  psychiatry nursing  health obesity  diabetes omics oncology and cancer therapeutics pharma physics social  political science related links psychiatry autism autistic disorder biosensor rigidity peripheral nerve robern medicine cabinets psychotherapy forensic odontology movement disorders speaker presentations pdfs speaker pdfs conferenceseries destinations conferences by continents usa  americas usa brazil canada mexico asiapacific  middle east australia china hong kong india indonesia japan malaysia new zealand philippines singapore south korea taiwan thailand uae europe austria denmark finland france germany italy netherlands norway poland south africa spain switzerland turkey uk ukraine medical  clinical conferences alternative healthcaredentistrydiabetes  endocrinologyhealthcare managementinfectious diseasesmedical ethics  health policiesneuroscienceobesityophthalmologypathologyphysical therapy rehabilitationradiologysurgerycardiologydermatologygastroenterologyimmunologymedicalmicrobiologynursingoncology  cancerpalliativecarepediatricspsychiatryreproductive medicine  women healthcarevaccines conferences by subject agri food  aquabusiness  managementchemistryenvironmental sciencesgeology  earth sciencematerials sciencenephrologypetroleumpharmaceutical sciencespulmonologyveterinarybiochemistrychemical engineeringeee  engineeringgenetics  molecular biologyhematologynanotechnologynutritionpharma marketing  industryphysicstoxicology contact us medical conferences jessie grace email protected 7 ext  pharmaceutical conferences badoni victor email protected 7 ext 7 immunology  microbiology conferences walker smith email protected 7 ext cancer conferences raul cliff email protected 7 ext nursing and healthcare conferences jennifer leny email protected 7 ext diabetes conferences stanley knight email protected 7 ext neuroscience conferences sandeep kumar email protected 7 ext dental conferences raul cliff email protected 7 ext clinical and biochemistry conferences rohit casper email protected 7 ext biotechnology conferences ravi vittal email protected 7 ext  material science conferences lucy grey email protected 7 ext genetics  mol biology conferences stephen bruce email protected 7 ext engineering conferences dolly a email protected 7 ext program enquiries symposiaworkshops sponsorships media partners  advertising    email protected b copyright   omics international all rights reserved takashi kei kishimoto  lexington ma  intelius sign in we found takashi kei kishimoto in lexington ma takashi kei kishimoto intelius found that takashi kei kishimoto is a male between  and  years old from lexington ma we have connected them to  addresses  phones and  relatives or associates get report now age takashi kei kishimoto is in his s takashi has lived in lexington ma framingham ma cambridge ma takashis relatives karen kishimoto kei kishimoto jamie kishimoto laura kishimoto takashi kei kishimoto zodiac signcapricorn gendermale professional status chief scientific officer at selecta biosciences  inc get report now want to know more about takashi get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about takashi or use our people search engine to find others get background check on takashi kei kishimoto get a criminal check on takashi kei kishimoto get a public record report on takashi kei kishimoto get a people search report on takashi kei kishimoto takashi kei kishimotos contact information known cities lived in find out where takashi kei kishimoto has lived as well as takashi kei kishimotos phone numbers and email addresses takashi kei kishimoto has lived in  states massachusetts address for takashi kei kishimoto  c a lexington ma has lived in lexington ma framingham ma get full address report phone numbers associated with takashi kei kishimoto 7   lexington ma 7   watertown ma    new fairfield ct get full phone report email addresses associated with takashi kei kishimoto tocom tocom tocom get email report takashi kei kishimotos professional information information regarding takashi kei kishimotos professional history find out previous places takashi kei kishimoto has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act takashi kei kishimoto has worked at  places company selecta biosciences  inc title chief scientific officer company selecta biosciences  inc title senior manager takashi kei kishimotos experience title chief scientific officer company selecta biosciences  inc job details company size  mil to less than  mil  employee range  to less than  selecta biosciences is a venture backed biopharmaceutical company based on pioneering research at the convergence of nanotechnology and immunology by professors robert langer omid farokhzad and ulrich von andrian at mit and harvard medical school selecta has assembled an experienced leadership team with extensive experience in drug delivery immunology and product development and is in the process of building a toptier collaborative and creative team to solve challenging chemical biological and engineering problems the ideal candidate will thrive in a fast paced science driven and exciting work environment focused on applying our product platform technology across multiple rd programs with the goal of greatly improving the lives of patients title senior manager company selecta biosciences  inc job details company size  mil to less than  mil  employee range  to less than  additional professional information on takashi kei kishimoto see takashi kei kishimotos linkedin profile takashi kei kishimotos social network and potential email matches find out potential social network profiles and potential email usernamed for takashi kei kishimoto takashi kei kishimotos known social networks and potential email matches find all of takashi kei kishimotos social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches takashi kishimoto username matches takashikishimoto kishimototakashi takashikishimoto kishimototakashi takashikishimoto kishimototakashi takashikishimoto kishimototakashi tkishimoto popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches t kishimoto intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here medical conferences in     cme conferences  usa  europe  asia  australia  uk  emedevents  takashi kei kishimoto menu home conferences conferences board review courses speakers organizers cme online more emed blogs emed news emed resources sign in create a conference header searcht ype conferences speakers organizers keyword search search date and time all dates next week next month custom date search customstartdate customenddate   home    speakers    takashi kei kishimoto conference session materials the conference session material has yet to be added by the speaker appears with adnan r khan andreas herrmann takashi kei kishimoto chief scientific officer  watertown massachusetts     specialties  biotechnology speaks about  immunology biotechnologymore spoken at  events speaking at  event track meet message summary upcoming past people biography  dr kishimoto is the chief scientific officer of selecta biosciences a biotechnology company developing synthetic vaccines based on a novel selfassembling nanoparticle technology prior to joining selecta he was vice president of research at momenta pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products previously he held leadership positions at millennium pharmaceuticals and boehringer ingelheim dr kishimoto has published over  peerreviewed articles including articles in nature science cell and the new england journal of medicine dr kishimoto received his doctoral degree in immunology from harvard university and his postdoctoral training at stanford university email  contact   social media info      for speakers contact information  contact us specialties biotechnology interested topics immunology biotechnology synthetic vaccines state licenses this section has yet to be updated by the speaker board certifications this section has yet to be updated by the speaker professional association this section has yet to be updated by the speaker languages english next close send message enter subject enter content send for physicians live cme courses board review courses cruise conferences medical journals online cme webinars podcasts daily medical news monthly briefings by specialty medical blog logistics medical conference registration conference reviews flight bookings hotel booking rent a car chauffeured services city guide and attractions best dinning in town international travel  visa requirements medical resources cme requirements by country  state ondemand cme medical societies by states medical societies by specialty medical certification  assessment boards medical licensure information medical councils and associations specialty certification boards quick links conferences in  conferences in  conferences in  suggested speakers speakers by country speakers by city speakers by specialty top  conferences top surgical conferences top dental conferences for organizers free listing of the conference online conference promotion online registrations customized organizer profile customized conference pages conference seo social media promotions targeted marketing find a speaker for event track your conference performance competitor analysis  data mining pharma  medical companies advertisement targeted marketing reach out to physicians data mining for speakers promote speaker profile network with peers and organizers related medical books publish your work customized speaker profiles emedevents about us  team our services contact us careers    pressroom success stories agreements advertise with us disclaimer privacy policy ☰ subscribe subscribe google twitter facebook linkedin linkedin apple apple terms  conditions  sitemap  security  cookies selecta biosciences appoints takashi kei kishimoto phd as chief scientific officer  selecta biosciences incselecta biosciences inc   about about selecta management team board of directors selecta russia collaborations contact platform svp™ platform svp™ for immune tolerance svp™ for immune stimulation publications pipeline pipeline overview mitigation of antidrug antibodies mitigation of antidrug antibodies gout gene therapy oncology allergies  autoimmune diseases therapeutic vaccines prophylactic vaccines investors  media investor overview press releases events  presentations stock information stock quote  chart historical price lookup investment calculator corporate governance highlights management team board of directors committee composition financial information sec filings annual reports annual meeting investor resources investor faqs ir contacts email alerts careers careers at selecta contact     press release selecta biosciences appoints takashi kei kishimoto phd as chief scientific officer watertown ma – august   – selecta biosciences inc a biopharmaceutical company developing novel targeted vaccines and immunotherapies announced today that takashi kei kishimoto phd has been appointed as chief scientific officer dr kishimoto brings more than  years of experience as a pharmaceutical and biotechnology scientist and leader he will report directly to werner cautreels phd chief executive officer of selecta biosciences “we are extremely pleased that kei will be joining our team to lead selecta’s scientific activities” said werner cautreels phd chief executive officer of selecta biosciences “kei’s experience will help to accelerate the advancement of our broad platform of synthetic vaccine particle svp™ product candidates which we view as central to leveraging the vast potential of selecta’s novel technology platforms” selecta’s breakthrough technology based on selfassembling synthetic nanoparticles creates a new paradigm in vaccine development enabling completely new therapeutic applications with improved efficacy and safety profiles “i am excited to have this opportunity to help develop the nextgeneration of therapeutic and prophylactic vaccines selecta’s unique synthetic vaccine particle svp™ platform has the potential to radically change how serious diseases such as cancer autoimmune diseases allergies and chronic infectious diseases are treated” said dr kishimoto “selecta’s broad technology platform has the power to both stimulate potent and protective immune responses as well as dampen deleterious immune responses in an antigenspecific manner” prior to joining selecta dr kishimoto was vice president of research at momenta pharmaceuticals where he led a multidisciplinary team in advancing both novel and complex generic products for inflammation oncology and cardiovascular disease previously he was senior director of inflammation research at millennium pharmaceuticals where he provided the scientific leadership for four programs in clinical development and was an associate director of research at boehringer ingelheim dr kishimoto has published over  peerreviewed articles in scientific journals including nature science cell and the new england journal of medicine dr kishimoto received his doctoral degree in immunology from harvard university and his postdoctoral training at stanford university about selecta selecta biosciences inc is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigenspecific immune activation or antigenspecific immune tolerance for therapeutic and prophylactic applications selecta’s proprietary synthetic vaccine particle svp™ platform creates a new paradigm in vaccine development enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles selecta’s fully synthetic engineering of novel vaccines offers a number of compelling benefits including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes selecta’s svp™ platform technology is flexible to enable diverse vaccines and the company has created targeted antigenspecific synthetic vaccine particles tsvp™ and targeted antigenspecific tolerogenic synthetic vaccine particles tsvp™ targeted synthetic vaccine particles tsvp™ activate immune responses to a wide array of relevant antigens including small molecules peptides oligosaccharides and proteins these particles can target humoral or cellular pathways of the immune system examples for applications include cancer infectious diseases and addiction targeted tolerogenic synthetic vaccine particles tsvp™ are designed to induce antigenspecific immune tolerance examples for applications include autoimmune diseases allergies and transplant rejection selecta’s pipeline currently contains a vaccine for smoking cessation and relapse prevention a vaccine for type  diabetes vaccines for several infectious diseases universal influenza universal human papillomavirus and malaria and research approaches with cancer vaccines and in the field of allergies building on the company’s novel approach selecta’s product candidates have the potential to become firstinclass or bestinclass therapeutics to treat and prevent diseases selecta biosciences is based in watertown massachusetts usa for more information please visit wwwselectabiocom media contact kathryn morris the yates network   kathryntheyatesnetworkcom  back to press releases   selecta biosciences inc all rights reserved    contact    sitemap   privacy policy    jobs at selecta biosciences       follow selectabio selb takashi kei kishimoto insider trades for selecta biosciences inc bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close selecta biosciences inc nasdaq selb go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus selecta biosciences inc after hours  quotes are delayed by  min jul    pm selb quoteszigman7composite   change   volume volume  quotes are delayed by  min quoteszigman7composite previous close  7   change   day low day high 7   week low  week high   insider activity individual takashi kei kishimoto dr takashi k kishimoto is chief scientific officer at selecta biosciences inc dr kishimoto was previously employed as vice presidentdiscovery research by momenta pharmaceuticals inc senior directorinflammation research by millennium pharmaceuticals inc associate directorresearch by boehringer ingelheim corp and vice presidentresearch by momenta corp he received his undergraduate degree from new college of california and a doctorate degree from harvard university transactions date shares transaction value     disposition at 7 per share 7     derivativenonderivative trans at  per share 77 copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr werner cautreels president chief executive officer  director dr lloyd johnston coo senior vice presidentresearch  development mr david l siewers chief financial officer  treasurer dr earl e sands chief medical officer dr takashi kei kishimoto chief scientific officer mr david abraham secretary compliance officer  general counsel mr peter keller chief business officer  headmedia relations mr timothy c barabe director dr timothy a springer director dr omid c farokhzad vice chairman mr jason fredette headinvestor relation mr ed m kania independent director dr carl lee gordon independent director mr peter barton hutt independent director dr aymeric sallin independent director dr amir h nashat independent director trending tickers quoteszigmancomposite vuzi quoteszigman77composite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ahca healthcare q factset eps consensus  ahca healthcare q eps 7 vs  a year ago acaterpillar beats earnings views lifts outlook atintri started at overweight with  stock price target at keybanc capital aneuralstem stock halted on news of midstage clinical trial miss 7atintri started at outperform with  stock price target at raymond james 7awebmd downgraded to market perform from outperform at raymond james 7aspectranetics downgraded to market perform from outperform at raymond james asierra bancorp upgraded to outperform from market perform at raymond james aalphabet stock price target raised to  from  at raymond james amcdonalds expects to net restaurant additions of  in  amcdonalds expects to have  experience of the future restaurants in us by end of  abreakingcaterpillar mcdonalds stocks set to add about  points to dow industrials aseagate technologys stock plunges after profit and sales miss ceo change aneuralstem stock halted on news of midstage clinical trial miss 7afreeportmcmoran shares gain  after company swings to a profit in q ainvesting lessons from edward thorp quant pioneer and card counter awe’re reaching the dangerous ninth inning for commercial real estate aneuralstem shares halted premarket for news pending awhat the solar eclipse on aug  will mean for stocks loading more headlines dow quoteszigman7realtime 7   nasdaq quoteszigmanrealtime    sp  quoteszigman7realtime    kiosk 7 7 the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml 7   alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml  7  location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml 7 7 7 lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice